Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Cytochrome P450 family protein | 0.0051 | 1 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0051 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0051 | 1 | 1 |
Trypanosoma brucei | cytochrome P450, putative | 0.0051 | 1 | 0.5 |
Leishmania major | cytochrome p450-like protein | 0.0051 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0051 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0051 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0051 | 1 | 0.5 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0051 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | Substrates of transporters of clinical importance in the absorption and disposition of drugs, MATE1 | ChEMBL. | 20190787 | |
Activity (ADMET) | Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT1 | ChEMBL. | 20190787 | |
Activity (ADMET) | Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT2 | ChEMBL. | 20190787 | |
Activity (ADMET) | Substrates of transporters of clinical importance in the absorption and disposition of drugs, MATE2-K | ChEMBL. | 20190787 | |
DA release (functional) | = 0.58 % | The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3) | ChEMBL. | 2374149 |
DA release (functional) | = 0.58 % | The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3) | ChEMBL. | 2374149 |
DA release (functional) | = 18 % | The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3) | ChEMBL. | 2374149 |
DA release (functional) | = 18 % | The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3) | ChEMBL. | 2374149 |
Inhibition (ADMET) | = -2.3 % | Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting | ChEMBL. | 22541068 |
Inhibition (ADMET) | = 12.8 % | Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting | ChEMBL. | 22541068 |
Inhibition (ADMET) | = 27.9 % | Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting | ChEMBL. | 22541068 |
Ki (binding) | > 10000 uM | Inhibition of [3H]-choline brain uptake was determined by in situ brain perfusion studies in male rats | ChEMBL. | 15149650 |
Ki (binding) | > 10000 uM | Inhibition of [3H]-choline brain uptake was determined by in situ brain perfusion studies in male rats | ChEMBL. | 15149650 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
4 literature references were collected for this gene.